Health Technology Assessment in Support of National Health Insurance in South Africa.


Journal

International journal of technology assessment in health care
ISSN: 1471-6348
Titre abrégé: Int J Technol Assess Health Care
Pays: England
ID NLM: 8508113

Informations de publication

Date de publication:
06 May 2022
Historique:
pubmed: 6 5 2022
medline: 7 6 2022
entrez: 5 5 2022
Statut: epublish

Résumé

South Africa has embarked on major health policy reform to deliver universal health coverage through the establishment of National Health Insurance (NHI). The aim is to improve access, remove financial barriers to care, and enhance care quality. Health technology assessment (HTA) is explicitly identified in the proposed NHI legislation and will have a prominent role in informing decisions about adoption and access to health interventions and technologies. The specific arrangements and approach to HTA in support of this legislation are yet to be determined. Although there is currently no formal national HTA institution in South Africa, there are several processes in both the public and private healthcare sectors that use elements of HTA to varying extents to inform access and resource allocation decisions. Institutions performing HTAs or related activities in South Africa include the National and Provincial Departments of Health, National Treasury, National Health Laboratory Service, Council for Medical Schemes, medical scheme administrators, managed care organizations, academic or research institutions, clinical societies and associations, pharmaceutical and devices companies, private consultancies, and private sector hospital groups. Existing fragmented HTA processes should coordinate and conform to a standardized, fit-for-purpose process and structure that can usefully inform priority setting under NHI and for other decision makers. This transformation will require comprehensive and inclusive planning with dedicated funding and regulation, and provision of strong oversight mechanisms and leadership.

Identifiants

pubmed: 35513309
doi: 10.1017/S0266462322000265
pii: S0266462322000265
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e44

Auteurs

Maryke Wilkinson (M)

Cochrane South Africa, South African Medical Research Council, Tygerberg, South Africa.
Mott MacDonald (Better Health Programme South Africa), Pretoria, South Africa.

Andrew Lofts Gray (AL)

Division of Pharmacology, Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.

Roger Wiseman (R)

Liberty Health (Pty) Ltd, Cape Town, South Africa.

Tamara Kredo (T)

Cochrane South Africa, South African Medical Research Council, Tygerberg, South Africa.
Department of Medicine and Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.

Karen Cohen (K)

Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Jacqui Miot (J)

Health Economics and Epidemiology Research Office, School of Clinical Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.

Mark Blecher (M)

National Treasury, Pretoria, South Africa.

Paul Ruff (P)

Division of Medical Oncology, Department of Medicine, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.

Yasmina Johnson (Y)

Pharmacy Services: Western Cape Government: Health, Cape Town, South Africa.

Mladen Poluta (M)

Health Technology Directorate: Western Cape Government: Health, Cape Town, South Africa.

Shelley McGee (S)

Ophthalmological Society of South Africa, Durban, South Africa.

Trudy D Leong (TD)

Essential Drugs Programme, National Department of Health, Pretoria, South Africa.

Mark Brand (M)

BRANDTECH Health Technology Consulting, Johannesburg, South Africa.

Fatima Suleman (F)

Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.

Esnath Maramba (E)

Clinical Unit, Council for Medical Schemes, Centurion, South Africa.

Marc Blockman (M)

Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Janine Jugathpal (J)

Essential Drugs Programme, National Department of Health, Pretoria, South Africa.

Susan Cleary (S)

Health Economics Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

Noluthando Nematswerani (N)

Strategic Risk Management, Discovery Health, Johannesburg, South Africa.

Sarvashni Moodliar (S)

Quality Assurance Division, National Health Laboratory Service, Johannesburg, South Africa.

Andy Parrish (A)

Department of Internal Medicine, Faculty of Health Sciences, Walter Sisulu University, Mthatha, South Africa.
Internal Medicine, Frere and Cecilia Makiwane Hospitals, East London, South Africa.

Khadija K Jamaloodien (KK)

Affordable Medicines Directorate, National Department of Health, Pretoria, South Africa.

Tienie Stander (T)

VI Research, Dubai, United Arab Emirates.

Kim MacQuilkan (K)

Mott MacDonald (Better Health Programme South Africa), Pretoria, South Africa.

Nicholas Crisp (N)

National Health Insurance, National Department of Health, Pretoria, South Africa.

Thomas Wilkinson (T)

Health Economics Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Health Nutrition and Population, World Bank, Washington, DC, USA.

Articles similaires

Humans Stress Disorders, Post-Traumatic Male Female Retrospective Studies
Humans Republic of Korea Female Male National Health Programs
Humans COVID-19 South Africa Community Health Workers Female

Classifications MeSH